Cholecystokinin does not stimulate prosomatostatin-derived peptides in man
- PMID: 1970830
- DOI: 10.1210/jcem-70-5-1403
Cholecystokinin does not stimulate prosomatostatin-derived peptides in man
Abstract
In man, plasma cholecystokinin (CCK) and somatostatin-28 (S-28) levels increase after ingestion of a mixed meal. Both peptides originate from the gastrointestinal tract. In supra- and periphysiological doses, CCK stimulates the release of somatostatin-14 from in vitro pancreatic islets and gastric cells and increases circulating somatostatin-like immunoreactivity in dogs, leading to the conjecture that CCK regulates somatostatin-like immunoreactivity secretion. Nonetheless, whether CCK is responsible in part for the meal-induced rise in S-28 in man has not been established. Therefore, the present study was designed to determine if CCK, at both physiological and supraphysiological concentrations, increases the circulating levels of prosomatostatin (proS)-derived peptides in humans. On 3 separate days, five healthy men ate a mixed liquid meal or received iv infusions of CCK at rates of 18 or 38 pmol/kg.h. Plasma levels of pro-S-derived peptides, including pro-S, S-14, S-13, S-28, and CCK, were measured. Basal CCK levels averaged 0.9 +/- 0.1 pmol/L and increased after the meal to a peak level of 5.4 +/- 1.5 pmol/L and averaged 3.1 +/- 1.2 pmol/L over 90 min. The mean basal levels of pro-S, S-14, and S-13, measured collectively, was 6.1 +/- 0.4 pmol/L eq S14 and was unaltered by food intake. The S-28 level was 6.7 +/- 0.6 pmol/L and rose to a zenith of 13.1 +/- 3.3 pmol/L by 90 min. Infusion of CCK at 18 and 38 pmol/kg.h produced steady state plasma CCK levels of 4.1 +/- 1.1 and 9.9 +/- 1.5 pmol/L, respectively. Basal levels of pro-S-derived peptides were unaltered during the infusion of either the low or high dose of CCK. We conclude that CCK by itself is not a physiological signal to the release of pro-S-derived peptides in man.
Similar articles
-
Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man.Diabetes Res Clin Pract. 1991 Sep;13(3):153-61. doi: 10.1016/0168-8227(91)90059-m. Diabetes Res Clin Pract. 1991. PMID: 1683622
-
Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans.J Clin Invest. 1988 Jun;81(6):1675-81. doi: 10.1172/JCI113505. J Clin Invest. 1988. PMID: 3290250 Free PMC article.
-
Cholecystokinin type A receptors mediate intestinal fat-induced inhibition of acid secretion through somatostatin-14 in dogs.Endocrinology. 1994 Jun;134(6):2376-82. doi: 10.1210/endo.134.6.7910794. Endocrinology. 1994. PMID: 7910794
-
Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.J Physiol Pharmacol. 1994 Dec;45(4 Suppl 1):3-66. J Physiol Pharmacol. 1994. PMID: 7787215 Review.
-
Integrated actions of cholecystokinin on the gastrointestinal tract: use of the cholecystokinin bioassay.Gastroenterol Clin North Am. 1989 Dec;18(4):735-56. Gastroenterol Clin North Am. 1989. PMID: 2482253 Review.
Cited by
-
The relationship between N-terminal prosomatostatin, all-cause and cardiovascular mortality in patients with type 2 diabetes mellitus (ZODIAC-35).BMC Endocr Disord. 2015 Apr 14;15:19. doi: 10.1186/s12902-015-0009-2. BMC Endocr Disord. 2015. PMID: 25880900 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous